Non-Cystic Fibrosis Bronchiectasis Cures
DISCLAIMER: CONSULT WITH A DOCTOR BEFORE DECIDING ON A TREATMENT PLAN FOR ANY DISEASE OR INJURY.
Non-Cystic Fibrosis Bronchiectasis (NCFB) is a respiratory disorder that involves chronically dilated airways, a chronic, persistent cough, and excessive sputum production. Patients with Non-Cystic Fibrosis Bronchiectasis often experience recurrent lung infections.
Serrapeptase Treatment for Non-CF Bronchiectasis
Serrapeptase is a proteolytic enzyme isolated from Serratia E15, a microorganism. This enzyme is often prescribed to patients because it improves sputum production and generally promotes wellness without causing side effects.
Molecular Hydrogen as a Cure for Non-CF Bronchiectasis
Though molecular hydrogen therapy has not been studied extensively in non-CF bronchiectasis, inhalation of molecular hydrogen has been used to cure diseases like cystic fibrosis, COPD, chronic bronchitis, and emphysema. Molecular hydrogen is a powerful antioxidant that is very safe and generally well-tolerated in patients with lung disease. The antioxidant function of molecular hydrogen has the ability to reduce inflammation in the airways, energize lung cells, and even, in some cases, repair DNA in the nucleus of human cells. Though molecular hydrogen therapy has not been studied as rigously in non-cystic fibrosis bronchiectasis, patients may benefit from this type of therapy, which is gentle and generally harmless. Typically, patients with COPD, emphysema, or cystic fibrosis must use molecular hydrogen inhalation treatments for 45 minutes daily for approximately one year to experience significant permanent healing.
Patients with non-cystic fibrosis bronchiectasis should consider using molecular hydrogen once daily for 45 minutes. Separate this dose of molecular hydrogen from chlorine dioxide doses by 1 hour to make sure that both of these medicines have time to work on the infection and inflammation in the body.
Chlorine Dioxide Solution and Dimethylsulfoxide (DMSO) as a Cure for Non-Cystic Fibrosis Bronchiectasis
Studies have shown that patients with non-cystic fibrosis bronchiectasis, often are infected with pathogens such as non-tuberculous mycobacteria that are either at the root of the disease or that are causing the disease to be worse. Chlorine dioxide solution is a substance that can be used to cure infections that would otherwise be untreatable using conventional medicine prescriptions such as antibiotics.
When combined with dimethylsulfoxide (DMSO), chlorine dioxide solution is even more powerful. DMSO is a molecule that’s electrically attracted to pathogens so it has the ability to seek out and destroy infections that would otherwise be unreachable using antibiotics that a doctor might prescribe. Combining DMSO with chlorine dioxide is a powerful combination that allows patients with non-cystic fibrosis brochiectasis to overcome infection without having to deal with the possibility of developing drug-resistant bacterial infections as a result of using pharmaceutically-based antibiotic therapy.
A number of scientific studies have shown that fungal infections are common in patients with both cystic fibrosis and non-CF bronchiectasis. Chlorine dioxide and DMSO are both able to kill fungal infections safely which gives the lung tissues an opportunity to heal.
Chlorine dioxide solution works by releasing reactive oxygen species that react with pathogens by causing a tiny explosion when they come into contact with them. Pathogens cannot become resistant to these oxygen species so patients who use this medicine can take it for longer periods of time or shorter periods of time to prevent or to cure infection. DMSO is FDA approved and it has a toxicity level similar to that of water. DMSO strengthens the effects of chlorine dioxide and ensures that it can reach even the most remote areas of the lungs that may be infected with pathogens, including those that are hiding under biofilm.
Halotherapy / Nebulizing with Salt for Non-Cystic Fibrosis Bronchiectasis
Halotherapy is a valuable treatment for patients with lung diseases and disorders, including non-cystic fibrosis bronchiectasis, for a few different reasons. In particular, some researchers believe that the primary reason why this treatment works well for non-cystic fibrosis bronchiectasis is because of the therapy’s following actions in the body:
- Improved mucociliary clearance
- Antibacterial effects (halotherapy has been studied in regard to its ability to control and/or completely eliminate bacterial infections, especially those in the lungs and/or nasal passages and sinuses)
- Regulation of metabolic mediators
- Regulation of serotonin secretion
- Rebalancing the oxidant-antioxidant system (too many oxidants OR antioxidants can cause problems in the body, and a balance must be maintained in order for a person to be healthy)
In one study done on a group of 20 patients with non-CF bronchiectasis, 65% of the participants receiving halotherapy experienced positive results and requested to continue the treatment even after the study had ended. Positive results were observed in almost every category of the study, though some categories of course had more significant changes than others. In particular, halotherapy most significantly improved scores on bodily pain, physical functioning, vitality, general health, and mental and emotional health summaries.
Halotherapy sessions generally last between 15-45 minutes depending on the patient’s situation and budget (one study completed on COPD patients with successful results administered 60 minutes of halotherapy per day for 10–25 days, 1-2 times per year, which may be used as a guideline when deciding how much halotherapy you’d like to receive). The recipient of the treatment sits in a manmade salt “cave” that is temperature regulated to 68 degrees Fahrenheit or less, where salt (sodium chloride) is ground into microscopic particles that are then released into the air. During the session, the patient breathes these microscopic salt particles into their lungs, nasal passages, and sinuses.
Below is a home-machine that can be placed beside the bed to produce tiny particles of salt that patients can breathe throughout the night for healing the lungs.
Hypertonic Saline Solution as a Natural Treatment for Non-Cystic Fibrosis Bronchiectasis
Hypertonic saline at a concentration of 6 to 7% has been used effectively to halt the progression of cystic fibrosis in both adults and children. Scientists, as a result, have also investigated the use of hypertonic saline as a natural treatment for non-cystic fibrosis bronchiectasis. Hypertonic saline is administered to patients with non-cystic fibrosis bronchiesctasis via a nebulizer. The substance works through various mechanisms of action including:
- Thinning of the mucus
- Restoration of airway moisture
- Stimulation of the cough reflex
- Removal of Pseudomonas aeruginosa biofilm in the lungs
Though the use of hypertonic saline in a nebulizer can stop the progression of obstructive lung diseases like bronchiectasis, about 8% of patients may experience a narrowing of their airways during the initial 10 uses of the medications. As such, it is important to have a health practitioner oversee the initial treatments with hypertonic saline so that airflow can be restored if the airways narrow too much.
Hypertonic Saline Plus Hyaluronic Acid 0.1% as a Cure for Non-CF Bronchiectasis
If you live in an area where you can obtain hypertonic saline 7% plus hyaluronic acid at 0.1%, this is a desirable option as a non-CF bronchiectasis cure. Hypertonic saline and hyaluronic acid mixed together provide a less “salty”-tasting treatment that is also less likely than hypertonic saline by itself to cause coughing or airway restriction during the initial treatments.
Choose a product that contains both hypertonic saline 7% and hyaluronic acid 0.1% rather than adding hyaluronic acid to the mixture. Many so-called “pure” hyaluronic acid products are not pharmaceutical-grade and may contains dangerous cancer-causing agents such as phenoxyethanol.
N-Acetylcysteine (NAC), Acetylcysteine or Cysteine as a Cure for Non-Cystic Fibrosis Bronchiectasis
N-acetylcysteine or NAC, acetylcysteine, and L-cysteine are related compounds. If you can’t get NAC as a cure for non-cystic fibrosis bronchiectasis, see if you can find either acetylcysteine or cysteine as alternative forms of treatment that also work very well against this disease.
Studies have shown that the long-term use of NAC can reduce exacerbation of bronchiectasis. It works by thinning mucus so that the mucus can more effectively clear toxins and pathogens from the body. Though NAC is one of the most powerful, natural lung detoxifiers available, it works through a mechanism of action similar to that of guaifenesin (except without any of the side effects caused by guaifenesin).
NAC is such a powerful detoxifier that often, those who take this medicine report that they experience much better moods while taking this medicine. It not only detoxifies the body specifically by making mucus more effective, but it also regulates the glutamatergic system. It has been used extensively as a natural treatment for mental health and addictions for this reason and many non-CF bronchiectasis patients experience positive results in terms of lung health and mental health while taking NAC, acetylcysteine, or L–cysteine.
Take NAC at 1000 mg up to 3 times per day to improve symptoms of non-cystic fibrosis bronchiectasis. If your doctor is willing to prescribe Mucomyst as an inhaler, this is also a valuable treatment for non-CF bronchiectasis.
Other Important Links:
Carro, L. M. and Martinez-Garcia, M. A. (2019). Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review. Retrieved March 12, 2022 from
Cuthbertson, L. et al. (2021). The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis. Retrieved March 12, 2022 from https://www.sciencedirect.com/science/article/pii/S1569199320301636
Rabbani, Bita, et. al. (2013). Efficacy of Halotherapy for Improvement of Pulmonary function Tests and Quality of Life of Non-Cystic Fibrosis Bronchiectatic Patients. Retrieved March 2, 2022 from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153239/
McDermott, Annette (2020). Does Halotherapy Really Work? Retrieved March 2, 2022 from: https://www.healthline.com/health/halotherapy#research
Mirsaeidi, M. et a. (2015). Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Retrieved March 11, 2022 from https://www.ncbi.nlm.nih.gov/sites/ppmc/articles/PMC4472485/
Watkins, B. (n.d.).Billie’s Wisdom. Retrieved March 12, 2022 from https://books.google.com.mx/books?id=FcGWBgAAQBAJ&pg=PA451&lpg=PA451&dq=serrapeptase+non-cystic+fibrosis+bronchiectasis&source=bl&ots=cevKCw7bM0&sig=ACfU3U2Iw0vFDFtVaP87NSlnK1Nf33-unA&hl=en&sa=X&ved=2ahUKEwjVsOyo4MH2AhWZkGoFHQB7B2sQ6AF6BAg_EAM#v=onepage&q=serrapeptase%20non-cystic%20fibrosis%20bronchiectasis&f=false